FDA issues warning on AAA (abdominal aortic aneurysms) endovascular graft devices
This article was originally published in Clinica
Executive Summary
The US FDA is warning physicians that serious problems, such as rupture and vessel damage, have occurred with the two endovascular graft devices now on the market for treatment of abdominal aortic aneurysms (AAA). The agency has not called for any change in how Guidant's Ancure System or Medtronic's AneuRx System are used. But its April 27 public health notification recommends that doctors make sure that all implanted patients are carefully followed and receive periodic follow-up imaging.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.